Skip to main content
Update Required: We noticed you are using an older version of Internet Explorer. To ensure full functionality of this site, please contact your system administrator to upgrade to the newest version of Internet Explorer or try accessing the site in Chrome.
HIROC
  • Home
  • Services
    • Risk Management
      Learn how our risk management solutions help you increase safety
    • Insurance
      Learn about our coverage offerings and how the HIROC advantage can work for you
    • Claims
      Learn about the claims process and the support HIROC provides
  • Resources
  • News & Events
    • Annual Conference
      Learn how the HIROC Annual Conference brings Subscribers, partners, and healthcare professionals together to drive patient safety forward
    • News
      News from HIROC and our subscribers about what’s trending in healthcare
    • Podcasts
      Podcasts from HIROC about healthcare
      • Healthcare Change Makers Podcast
      • Share Scale Repeat Podcast
    • Webinars and Events
      View our schedule of upcoming webinars and access the archives
  • About Us
    • Board of Directors
      Learn about our Board – made up of HIROC subscribers – and access the current list of Directors
    • Leadership Team
      A message from HIROC's CEO, Catherine Gaulton
    • Careers
      Want to join a team of innovators and leaders? Check out our current opportunities
    • Our Story, Our Art of Safety Strategy
      How HIROC and its Subscribers are working to create the safest healthcare system
    • Risk Management Residency Program (RMRP)
      Learn about the RMRP
    • Safety Grants Program
      Learn about the HIROC Foundation and the Safety Grants Program
  • Contact Us
Log in Register
HIROC
Log in Register
  1. Home
  2. Resources
  3. Induction and Augmentation and the “Crash” C-Section

Related Resources

Risk Watch (October '25)

Download PDF

Members Only

Webinars

Documentation: Answers to Frequently Asked Questions

Care

Risk Case Studies

Patient/Client Falls

Download PDF

Induction and Augmentation and the “Crash” C-Section

Category
Care
Topic
Obstetrics
Type
Risk Case Studies
  • Download PDF
  • LinkedIn

Key Words

Obstetrics, Acute Care, Interprofessional Communication, Monitoring, High Alert Medication, IV Oxytocin, Induction and Augmentation, Fetal/Patient Deterioration

Abstract

A young low risk maternal patient underwent a ‘crash’ c-section due to abnormal fetal heart rate (FHR) patterns. Failure to discontinue IV oxytocin and poor interprofessional communication practices were identified as contributing factors.

Case Summary

A young maternal patient presented to the local hospital for the birth of her second child. Considered a low-risk patient, the patient had an unremarkable medical history, and a normal pregnancy absent of any noted complications.

One hour following the patient’s admission to the obstetrics unit, the patient’s FHR pattern fluctuated between atypical and abnormal; the nurse also noted decelerations. The nurse proceeded to increase the patient’s intravenous fluids (IV), change the patient’s position and continued to increase the rate of IV oxytocin.

One hour later, the patient began to push. The nurse continued to increase the patient’s IV oxytocin throughout. After forty minutes of pushing, the nurse called the attending family physician to assess. Following the assessment, the family physician instructed the patient to rest – oxygen and fluids were administered, with several position changes initiated.

Half an hour after the assessment, the nurse consulted the program leader to assess the patient, as result of ongoing concerns related to the FHR pattern. Shortly thereafter, the family physician returned to the patient’s room and ordered the discontinuation of the oxytocin infusion. Ten minutes later, the nurse initiated fetal scalp stimulation and paged the family physician. Upon reviewing the fetal heart strip, the decision was made to proceed with a ‘crash’ c-section.

The infant was born with Apgars of 1 and 4 at 1 and 5 minutes. Diagnosed with severe hypoxic ischemic encephalopathy, the infant was transferred to a paediatric care facility.

Medical legal findings

Legal findings

Expert review of the case was critical of the care provided to the maternal and fetal patients, noting that IV oxytocin should have been discontinued by nursing following the identification of abnormal FHR patterns. A review of the patient’s chart revealed that the obstetrician who had initially admitted the patient to the obstetrics unit had ordered that the oxytocin infusion be discontinued once pushing commenced. Experts were critical of the involved nurse and family physician’s failure to comply with the obstetrician’s order. Experts also questioned whether the nurses relayed the degree of urgency necessary when communicating the fetal status to the patient’s obstetrical primary care provider.

Reflections

Reflecting on your practices as well as your facility’s monitoring and induction/augmentation policies, procedures and processes:

  1. IV oxytocin is a high-alert medication as identified by the Institute for Safe Medical Practices (ISMP). Further, the mismanagement of induction/augmentation medication is the fourth highest ranked risk (by claims costs) for hospitals as identified by HIROC.
    • Describe what is considered a ‘high-alert’ medication? Names some examples of high-alert medications.
    • Describe some of the system issues and practitioner errors involving IV oxytocin? What are some effective strategies to reduce such issues/errors? Have such strategies been widely adopted and integrated into day to day practice across your unit/program?
  2. Reflecting on your local policy/protocol, do nurses and midwives require a physician order/consult to turn down or turn off IV oxytocin? Discuss whether practitioners are professionally accountable for accepting and instituting an order, including increasing the rate of IV oxytocin infusion, in the presence of contraindications (e.g. abnormal fetal heart rate patterns).
  3. Why is a bedside assessment by the ordering/consultant physician encouraged before accepting or instituting an order for IV oxytocin? Is the routine practice of verbal orders for IV oxytocin acceptable? Is your program’s culture permissive of routine verbal orders for IV oxytocin?
  4. Discuss the specific steps/action staff and learners should take if they disagree with the clinical decision/ recommendation of the most responsible practitioner or consultant (for example, recommendation to increase the rate of infusion in the presence of ongoing atypical and abnormal fetal heart rate patterns)? Discuss the concepts of ‘escalation’, ‘chain of command’ and ‘culture’ as they related to patient safety.
  5. Describe your program oxytocin-dosing protocol (who, what, why, when and how). Discuss the benefits of adopting a standardized oxytocin protocol.
Date last reviewed: October 2017
This is a resource for quality assurance and risk management purposes only, and is not intended to provide or replace legal or medical advice or reflect standards of care and/or standards of practice of a regulatory body. The information contained in this resource was deemed accurate at the time of publication, however, practices may change without notice.

Related Resources

Risk Watch (October '25)

Download PDF

Members Only

Webinars

Documentation: Answers to Frequently Asked Questions

Care

Risk Case Studies

Patient/Client Falls

Download PDF

Partnering to create the safest healthcare system

HIROC is not just a not-for-profit, we are a reciprocal. This means we are governed by our Subscribers – a group of over 800 diverse healthcare organizations across Canada. Together we share learnings and find ways to adapt to the changing nature of the industry.
Learn More
HIROC staff members
HIROC
Join our newsletter to stay up to date with the latest news.
By subscribing you agree with our Privacy Policy and provide consent to receive updates from HIROC.

About Us

  • Careers
  • Contact Us
  • Our Story, Our Art of Safety Strategy
  • Risk Management Residency Program (RMRP)
  • Safety Grants Program

Quicklinks

  • Claims
  • Insurance
  • Risk Management

Important information

  • Privacy Policy
  • Cookie Policy
  • Terms and Conditions
  • AODA

©2026 HIROC All rights reserved.

  • Linkedin
  • Instagram
  • Youtube